Nanobiotix (NASDAQ:NBTX) Shares Up 7.9% – Time to Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) rose 7.9% during trading on Tuesday. The stock traded as high as $32.25 and last traded at $33.0390. Approximately 1,339 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 99,621 shares. The stock had previously closed at $30.63.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NBTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, October 15th. Guggenheim initiated coverage on Nanobiotix in a report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $46.67.

Nanobiotix Stock Up 0.2%

The firm’s fifty day moving average price is $30.71 and its 200-day moving average price is $34.11.

Nanobiotix Company Profile

Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy. Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.